KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094-108.

Li Ding, Bin Yang, Xudong Yao

Eur Urol 86(4) e88-e89

PMID38000965
PMCID-
DOI10.1016/j.eururo.2023.10.024
发表日期2023-11-24
摘要

摘要

无摘要

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。